home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next

Next-Generation Tools for Cell Therapy Characterization and Monitoring

  January 16, 2023  
Xtalks, online
2023 -2-22

Last March, the U.S. Food & Drug Administration (FDA) issued updated guidance related to cell therapy characterization, manufacturing and monitoring. Historically, tools that were developed for gene therapies have been repurposed for cell therapy monitoring; however, they have limitations including repeated validation requirements, limited assay sensitivity and suboptimal quantitative accuracy. Several quantitative assays are now available specifically for cell therapy—providing single-cell resolution for quantifying vector copy number, counting therapeutic cells and tracking individual clones. These assays may help improve cell therapy products at every stage, from process development, to manufacturing and patient monitoring.
In this webinar, attendees will dive into the FDA’s latest guidance for monitoring the quality, safety and efficacy of cell therapies and learn how a single-cell assay combined with high-throughput T-cell receptor (TCR) sequencing can provide a next generation solution for characterizing and tracking cell therapies.
Register to gain more insight into the next-generation tools for cell therapy characterization, manufacturing and monitoring.
Organized by: Xtalks
Invited Speakers: Alex Dahmani, Director, Immune Medicine, Adaptive Biotechnologies Vincenzo Di Cerbo, PhD, Lead Scientist, Cell and Gene Therapy Catapult
Deadline for Abstracts: 2023 -2-22
Registration: Free registration
E-mail: ajuurinen@xtalks.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.